Less than a week after postponing its initial public offering, West L.A. medical device maker NeuroSigma announced Wednesday that it has entered into a research and development agreement with U.S. Veterans Affairs for a clinical trial.

The trial will evaluate the benefits of a NeuroSigma nerve stimulation device on patients with traumatic brain injury, or TBI.

“There is an acute need for more non-invasive TBI treatment options, not only for our veterans returning from overseas combat operations but also for the millions of Americans involved in motor vehicle accidents, falls and sports-related concussions,” said Lodwrick M. Cook, chairman of NeuroSigma.

NeuroSigma in 2012 was approved to market a nerve stimulation device in the European Union for the treatment of epilepsy and major depressive disorder. In its new project with the VA, veterans with traumatic brain injuries will receive NeuroSigma’s system nightly in their own homes for an eight-week period.

The device, called the Monarch eTNS, provides gentle stimulus to a particular nerve through disposable electrode pads that patients can wear while sleeping.

NeuroSigma last week postponed its $50 million initial public offering, citing poor market conditions.

For reprint and licensing requests for this article, CLICK HERE.